🏢Fintech / Brokers
Groww vs. Angel One vs. Zerodha — Key Findings (June 3–5):
- Tech infrastructure:Â Groww migrated to CockroachDB cell-based architecture with Row-Level Data Homing, limiting blast radius during outages. Zerodha had 4 glitches in FY26 (till Feb) vs. Groww’s 1.
- Active users: In FY26, only Groww grew active user count; also the only one with steadily rising revenue per active user. Note: ARPU appears lower because it’s reported quarterly — annualizing moves it to ~â‚ą3,600, showing improvement over FY25.
- Regulatory clean record:Â Groww and Zerodha’s pure-play D2C model vs. Angel One’s sub-broker franchise architecture explains the SEBI settlement gap.
- PFIC advantage for US NRIs: PMS via separate account is not classified as a PFIC by the IRS; capital gains taxed at 15–20% vs. up to 37% + compound interest penalty under default PFIC rules. PMS + GIFT City = best vehicle for US NRI clients.
- Angel One updates:Â New CTO Ajit Narayanan (ex-Reliance Retail, Licious, Myntra, MFine) hired. Monthly update: commodities driving growth. Rategain moved before the 21-day monitoring window completed.
- GIFT City: Zerodha, Groww, Angel One, Upstox all received GIFT City nod to offer US stocks to Indian investors (June 16).Â
🏥Healthcare / Hospitals
Thyrocare — Deep Dive (June 12):
- Business model evolution: pay-for-performance pricing, B2B/insurance expansion, specialty testing (histopathology, genomics), “string of pearls” acquisitions (Polo Labs – North, Vimta – South), exited low-margin B2G, first JV lab launched in Tanzania.
- Quality: Average TAT dropped to 3.28 hours; Pan-India P90 TAT ≤ 18 hours; defect rate down to 3.06 per million tests (Six Sigma); India’s first 100% NABL-accredited national lab chain.
For Hospitals break-even for new facilities is declined to 1.5 years from 5 years a decade ago
KIMS — Greenfield Breakeven Accelerating:
- Now 1–2 years from 5–6 years a decade ago. Key drivers: doctor equity partnership model, better talent availability, stronger brand in South India, micro-market selection, asset-light O&M models, rising insurance penetration.
Medanta — Noida Facility:
- NOT breaking even faster; management framing it as a deliberate investment upfront in clinical talent. Gurgaon 2009 hospital broke even in 18M — making Noida look like a company-specific delay, not sector-wide.
MAXH: Greenfield breaking even faster — positive signal.
HCG — Governance Flag:
- New CMO: Manu (ex-MediBuddy, RedBus).
- CDSCO suspended HCG KR Unit Ethics Committee for 24 months over clinical trial violations (failure to report Serious Adverse Events). Company says no material financial impact; isolated unit.
Sector: Private hospitals expected to deliver 14–15% revenue growth in FY27.
đź’ŠCDMO / Pharma
NFIL (Navin Fluorine) — CDMO Diversification:
- Fermion commercial deliveries commenced post validation batches in Q3FY26; expected to be 35–40% of $100M CDMO target.
- “Next Fermion” EU molecule: repeat orders secured for CY26; clinical readout expected Nov/Dec 2026 — could be another Fermion-scale opportunity.
- Third EU major also in late-stage pipeline; audits cleared with three distinct global pharma innovators.
- Pipeline: ~50–55 molecules; 50-50 early/late-stage split.
WuXi AppTec — Pentagon Ban (June 8, 2026):
- WuXi now included in the updated Pentagon banned entity list. Strong US Govt intent signals structural multi-year tailwind for Indian CDMOs. Drug supply chain shifts take years — pharma companies need to act now, before restrictions tighten further. Positive for NFIL, Divi’s, and the broader India CDMO basket.
Refrigerant Gases (June 19):
- HFC-32: export volumes +80% YoY, spreads +84% to ₹603/kg.
- HFC-134A: spreads +120% YoY to ₹1,000/kg — best performer.
- HFC-125: volumes +16%, spreads +55%.
- HCFC-22: volumes down 62%, spreads contracting — pricing pressure.
⚡Capital Goods / T&D
Schneider Electric — Positioning Note:
- Focused on medium-voltage (transformers up to 170kV) — not an EHV (220kV+) player like GE, Hitachi, Siemens Energy, CG. Top 3 in MV alongside ABB and Siemens.
- End markets: Power & Grid, Manufacturing, Mobility, Data Centres.
- Order inflow growth slowed to 1% in Q4FY26 — watch for acceleration.
Solar Industries: Deepening integration into the BrahMos supply chain (100th indigenous booster rolled out).
Action Construction Equipment: Defense expected to scale from ~3% of revenue (FY26) to 5–6% or ₹200–220 Cr in FY27.
đź’»IT Services / AI Disruption
- Morgan Stanley CIO Survey 2026: Total IT budgets growing 3.7%, but IT services budgets growing only 2% — AI is cannibalizing ~40% of incremental IT services growth through in-house adoption.
- TCS Chairman:Â “Will not be hiring the kind of numbers it used to hire.”
- MapMyIndia: Management dismisses AI disruption risk — their data creation has been AI-enabled for years; map data is proprietary and government-protected at granular level. Q3 FY26 billing deferral from private clients (wanting more AI in scope) was temporary and now resolved.
đź›’Quick Commerce
- Blinkit called the best: fastest growing, profitable at scale.
- Last-mile cost: QC at 5–6% of AOV vs food delivery 9–10% (density advantage).
- Zepto:Â Gross margin ex-ad revenue 10%, including ad revenue 18.5% vs DMart 13.5%.
- QC industry volume context: entire industry ~200 Cr orders in CY25 (Blinkit ~80 Cr); Meesho alone did 265 Cr orders in FY26 — underscores QC’s relative infancy.
🌍Macro
RBI FCNR(B) / ECB Swap Scheme:
- Zero-premium dollar-rupee swap for NRI 3-5Y deposits; banks can offer high rates, attracting carry trade. CRR/SLR exempted. PSU ECBs at 1.5% fixed swap cost. Window open till Oct 16, 2026 (FCNR) / Jan 15, 2027 (ECB). Expected to attract $40–50B in inflows.
FPI Flows:
- Indian equities peaked September 2024; FPIs sold $51B through April 2026. Foreign holding fell from $930B → $670B (a ~30% drop in market value).
- Union Cabinet approved ordinance exempting capital gains tax on G-Secs for FPIs to stem outflows.
US Fed:
- Kevin Warsh’s commentary + new projections shifted rate hike expectations to October 2026 (60.7% probability per CME FedWatch), from December previously.